Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
Silo Pharma(SILO) Newsfilter·2024-07-08 20:45
Extensive Issued and Pending IP Patent Applications Acquired with License Agreement SARASOTA, FL, July 08, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive, global license agreement with Columbia University to further develop, manufacture, and commerc ...